Scholarlink

Background <p>The coronavirus disease (COVID-19) pandemic indeed strains healthcare systems worldwide, resulting in a surge of patients with severe conditions. Numerous physiological severity scores have been assigned to assess critical conditions; however, a comprehensive comparison of these scoring systems remains lacking. Therefore, this study aimed to evaluate the performance of the severity scores upon admission in predicting the progression of COVID-19 patients to a severe condition within 14 days after hospitalization.</p> Methods <p>Non-critically ill COVID-19 patients admitted to the Faculty of Medicine, Vajira Hospital, between 1 January 2021 and 30 June 2021, were assessed. We compared the discriminated ability of physiological severity scores in predicting disease progression to critical conditions using the area under the receiver operating characteristic curve (AUC).</p> Results <p>Totally, 348 non-critically ill COVID-19 patients were included. Of these, 60 patients (17.2%) progressed to severe conditions within 14 days after hospitalization. The National Early Warning Score 2 with age and body mass index (NEWS2 Plus) was the most outperformed than the National Early Warning Score (NEWS), the National Early Warning Score 2 (NEWS2), the Hamilton Early Warning Score (HEWS), the Modified Early Warning Score (MEWS), and the quick Sepsis-related Organ Failure Assessment (qSOFA) scores, for predicting deterioration to severe conditions [AUC 0.77 (95% CI; 0.72-0.83)]. The NEWS2 Plus with a cutoff point of five exhibited high sensitivity (83.3%) and high negative predictive value (NPV) of 94.7%.</p> Conclusions <p>NEWS2 Plus score can enhance its utility for triage of COVID-19 patients’ clinical status upon admission and guide appropriate management decisions for resource allocation.</p> Trial registration <p>TCTR20241026001, registered on 26 October 2024.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of physiological severity scores for predicting COVID-19 disease progression: a retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月26日

查看全文
  • Sujaree Poopipatpab,
  • Ratchaya Weerayutwattana,
  • Pruchwilai Nuchpramool,
  • Piyarat Phairatwet,
  • Tospon Lertwattanachai,
  • Konlawij Trongtrakul

摘要

Background

The coronavirus disease (COVID-19) pandemic indeed strains healthcare systems worldwide, resulting in a surge of patients with severe conditions. Numerous physiological severity scores have been assigned to assess critical conditions; however, a comprehensive comparison of these scoring systems remains lacking. Therefore, this study aimed to evaluate the performance of the severity scores upon admission in predicting the progression of COVID-19 patients to a severe condition within 14 days after hospitalization.

Methods

Non-critically ill COVID-19 patients admitted to the Faculty of Medicine, Vajira Hospital, between 1 January 2021 and 30 June 2021, were assessed. We compared the discriminated ability of physiological severity scores in predicting disease progression to critical conditions using the area under the receiver operating characteristic curve (AUC).

Results

Totally, 348 non-critically ill COVID-19 patients were included. Of these, 60 patients (17.2%) progressed to severe conditions within 14 days after hospitalization. The National Early Warning Score 2 with age and body mass index (NEWS2 Plus) was the most outperformed than the National Early Warning Score (NEWS), the National Early Warning Score 2 (NEWS2), the Hamilton Early Warning Score (HEWS), the Modified Early Warning Score (MEWS), and the quick Sepsis-related Organ Failure Assessment (qSOFA) scores, for predicting deterioration to severe conditions [AUC 0.77 (95% CI; 0.72-0.83)]. The NEWS2 Plus with a cutoff point of five exhibited high sensitivity (83.3%) and high negative predictive value (NPV) of 94.7%.

Conclusions

NEWS2 Plus score can enhance its utility for triage of COVID-19 patients’ clinical status upon admission and guide appropriate management decisions for resource allocation.

Trial registration

TCTR20241026001, registered on 26 October 2024.